OWC PHARMACEUTICAL RESEARCH CORP. (OTCMKTS:OWCP) Files An 8-K Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities.

During the period from January 9, 2017 through February 22, 2017,
OWC Pharmaceutical Research Corp. (the Registrant or the Company)
issued and sold to accredited investors, as that term is defined
in Rule 501 under Regulation D promulgated by the Securities and
Exchange Commission under the Securities Act of 1933, as amended
(the Act) units comprised of restricted shares of the
Registrant’s common stock, par value $0.0001 (the Shares) and
common stock purchase warrants, as follows:

(i) On February 22, 2017, a total of 550,000 units at a price of
$0.70 per unit, each consisting of one Share and on one Class L
Warrant exercisable at $1.40 for a period of 18 months for total
proceeds of $385,000; (ii) On February 13, 2017, a total of
1,734,000 units at a price of $0.50 per unit, each consisting of
one Share and one Class K Warrant exercisable to $1.00 for a
period of 18 months for total proceeds of $867,000; (iii) On
January 17, 2017, a total of 520,000 units at price of $0.25 per
unit, each consisting of one Share and one Class I Warrant
exercisable at $0.50 for a period of 24 months for total proceeds
of $130,000; (iv) On January 13. 2017, a total of 588,235 units
at $0.17 per unit, each consisting of one Share and one Class H
Warrant exercisable at $0.40 for a period of 36 months, for total
proceeds of $100,000; and (v) On January 9, 2017, a total of
1,097,230 units at $0.13 per unit, each consisting of one Share
and one Class G Warrant exercisable at $0.25 for a period of 24
months and one Class H Warrant exercisable at $0.40 for a period
of 36 months for total proceeds of $142,640.

In addition, on February 3, 2017, the Registrant issued a total
300,000 restricted Shares to Lyons Capital, LLC, a Florida
limited liability company, for business consulting services as
well as the Registrant’s participation in 2017 WSC Conference
Event being held at the Hilton Double Tree, Boca Raton, FL on
March 1, 2017.

The issuance of the Shares and Warrants was made in reliance upon
the exemptions provided in Section 4(2) of the Securities Act of
1933, as amended (the Act) and Regulation S and Regulation D
promulgated by the SEC under the Act.

Item 8.01. Other Events.

The Registrant, in its press release attached hereto as Exhibit
99.1 to this 8-K, announced it has received Institutional Review
Board (IRB) approval to conduct safety testing on its proprietary
topical creme compound for the treatment of psoriasis and related
skin conditions. Psoriasis is an autoimmune disease that causes
red, scaly patches to appear on the skin, and can be associated
with other serious health conditions, including diabetes, heart
disease and depression. According to the National Psoriasis
Foundation, psoriasis affects 7.5 million people in the United
States.

The IRB approval follows the Company’s February 1, 2017 8-K
filing announcing an extension to the size and scope of its
efficacy study on the same compound, which began in November
2106. The IRB-approved study encompasses the cream itself, as a
delivery mechanism, as well as the proprietary psoriasis
formulation, and is the first to formally make such claims with
the NIH Registry. The double-blind study, which will be conducted
on healthy volunteers at one of Israel’s leading academic
hospitals, is designed to demonstrate the safety of the
formulation in treating psoriasis on human skin tissue.

Dr. Yehuda Baruch, the Company’s Director of Research and
Regulatory Affairs, stated This approval is a significant
milestone for OWC, where our mission is to bring the same
rigorous approach common to traditional pharmaceutical
development to the medical cannabis field. As we reported
earlier, the results of our efficacy studies were so encouraging
that management decided to extend the size and scope of the study
to verify the biological markers that had been generated to date,
among other things.

Ziv Turner, the Company’s Vice President of Business Development
and Managing Director of One World Cannabis, Ltd., the Company’s
wholly-owned subsidiary, added, immediately following
announcement of the Company’s psoriasis treatment formulation,
we began receiving requests for our topical psoriasis cream
product from patients suffering from the condition. After several
years of extensive commitment to RD, we now expect that the
Company should be in position to bring our psoriasis cream
product to the market during the second quarter of 2017 or soon
thereafter.

Reference is made to the full text of the press release filed as
Exhibit 99.1 herewith.

Item 9.01 Financial Statements and Exhibits.

(a) The following documents are filed as exhibits to this report
on Form 8-K or incorporated by reference herein. Any document
incorporated by reference is identified by a parenthetical
reference to the SEC filing that included such document.

About OWC PHARMACEUTICAL RESEARCH CORP. (OTCMKTS:OWCP)

OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.

OWC PHARMACEUTICAL RESEARCH CORP. (OTCMKTS:OWCP) Recent Trading Information

OWC PHARMACEUTICAL RESEARCH CORP. (OTCMKTS:OWCP) closed its last trading session up +0.33 at 2.19 with 6,498,403 shares trading hands.